Amylyx Pharmaceuticals Announces Positive Phase 3 LUCIDITY Results

What Happened
Amylyx Pharmaceuticals, Inc. announced on August 18, 2026 that it shared positive topline results from the LUCIDITY Phase 3 clinical trial evaluating avexitide in participants with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery. The company hosted a conference call with investors and analysts the same day and attached selected presentation slides as Exhibit 99.1 to the Form 8-K.

Key Details

• Event date: August 18, 2026 — conference call with investors and analysts to discuss results.
• Trial: LUCIDITY Phase 3 evaluating avexitide for post-bariatric hypoglycemia after Roux-en-Y gastric bypass.
• Filing: Results and slides were disclosed in a Current Report on Form 8-K; Exhibit 99.1 contains the presentation slides.
• Nature of data: Described as "positive topline results" (detailed efficacy/safety data and next steps were not included in the 8-K).

Why It Matters
Positive Phase 3 topline results are a major clinical milestone. For investors, this update signals progress toward potential regulatory submissions and commercialization planning for avexitide in a specific post-bariatric hypoglycemia indication. Watch for follow-up disclosures with full data, regulatory plans, and timelines — those details will be important for assessing the program’s commercial and financial impact.